These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34586753)

  • 1. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions.
    Matharu K; Chana K; Ferro CJ; Jones AM
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00867. PubMed ID: 34586753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
    Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
    Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
    Donnan JR; Grandy CA; Chibrikov E; Marra CA; Aubrey-Bassler K; Johnston K; Swab M; Hache J; Curnew D; Nguyen H; Gamble JM
    BMJ Open; 2019 Feb; 9(1):e022577. PubMed ID: 30813108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
    McGill JB; Subramanian S
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S45-S52. PubMed ID: 31741440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
    Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
    Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
    Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
    Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.
    Heyward J; Mansour O; Olson L; Singh S; Alexander GC
    PLoS One; 2020; 15(6):e0234065. PubMed ID: 32502190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
    Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
    Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis.
    Luo Y; Bai R; Zhang W; Qin G
    Front Endocrinol (Lausanne); 2024; 15():1333624. PubMed ID: 38362282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
    Jabbour S; Seufert J; Scheen A; Bailey CJ; Karup C; Langkilde AM
    Diabetes Obes Metab; 2018 Mar; 20(3):620-628. PubMed ID: 28950419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.